Anders Tullgren joins BerGenBio

Thursday 13 January 2022
BerGenBio ASA
Appointee name
Anders Tullgren


Anders Tullgren has been appointed chairman of the board of directors at BerGenBio ASA bringing with him more than 35 years of experience in the global pharmaceutical industry of which more than 20 were spent at Bristol Myers Squibb Co. At BMS, he was most recently president of the intercontinental region overseeing the company’s businesses across 30 countries. He will succeed Sveinung Hole who has chaired the board since March 2019 and will continue as a board member.

Mr Tullgren holds an MSc in pharmaceutical studies from Uppsala University and a diploma in marketing and business administration from Management Information Systems, both in Sweden. BerGenBio is developing an AXL inhibitor for cancer.

BerGenBio announced the appointment on 6 January 2022.

Copyright 2022 Evernow Publishing Ltd